RARITAN, N.J., July 7, 2021 /CNW/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play, in-vitro diagnostics (IVD) companies, today announced its distribution agreement ...

-- Ortho's new VITROS(R) Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent ...

Raritan-based Ortho Clinical Diagnostics said April 3, it is launching to market its COVID-19 antibody test. The VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack testing kits are ...

RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ...

Ortho-Clinical Diagnostics is a global leader in in vitro diagnostics. The company specializes in blood testing and screening products and services. Ortho-Clinical Diagnostics has over 4,500 employees ...

- Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians ...

After a blockbuster two years bolstered by sales of its multiple COVID-19 diagnostics, Quidel is looking for a way to reinvest that windfall back into the business—and seems to have found it in the ...

Ortho Clinical Diagnostics is hoping to pay down a large portion of its debts by riding a wave of COVID-19 and broader in vitro lab testing demands to a $1.5 billion IPO. The company is offering 70 ...

• Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in ...

Raritan’s Ortho Clinical Diagnostics Holdings plc and Quidel Corp., based in San Diego, on Dec. 23 announced entering a definitive agreement that will see Quidel acquire Ortho in a deal valued at ...

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced it is working with Quest ...